Xiidra Acquisition

Xiidra Acquisition



Novartis to acquire Xiidra®, expanding front-of-eye portfolio and strengthening leadership in eye care #Xiidra (lifitegrast ophthalmic solution) 5% fits strategically within industry-leading USD 4.6 billion Novartis ophthalmic pharmaceutical portfolio, laying groundwork for front-of-the-eye pipeline products currently in development [1] Xiidra is the first and only prescription treatment approved for both signs and symptoms of dry eye disease with a mechanism of action that targets inflammation[2] Xiidra achieved USD 0.4 billion of revenue in 2018 and is well positioned for blockbuster potential closing expected in second half of 2019, subject to satisfaction of customary closing conditions, … Deal terms include a USD 3.4 billion upfront payment with potential milestone payments of up to USD 1.9 billion, 7/1/2019  · Novartis successfully completes acquisition of Xiidra®, bolstering ophthalmic portfolio. Back to News Archive. Jul 01, 2019. Basel, July 1, 2019 – Novartis today announced that it has completed its acquisition of Xiidra® (lifitegrast ophthalmic solution) 5%, the first and only prescription treatment approved to treat both signs and symptoms of dry …


5/8/2019  · Xiidra is the first and only prescription treatment approved for both signs and symptoms of dry eye disease with a mechanism of action that targets inflammation[2] Xiidra achieved USD 0.4 billion of revenue in 2018 and is well positioned for blockbuster potential closing expected in second half of 2019, subject to satisfaction of customary closing conditions, including regulatory approvals, 7/1/2019  · July 1, 2019 Osaka, Japan. Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its sale of its Xiidra ® (lifitegrast ophthalmic solution) 5% product to Novartis for $3.4 billion upfront in cash and up to an additional $1.9 billion in potential milestone payments.


Basel, July 1, 2019 – Novartis today announced that it has completed its acquisition of Xiidra ® (lifitegrast ophthalmic solution) 5%, the first and only prescription treatment approved to treat …


The FDA approved Xiidra in 2016, becoming just the second drug approved in the United States for dry eye disease, joining Allergan’s Restasis (c yclosporine ophthalmic emulsion) 0.05%, which was approved in 2003. Takeda acquired the rights to Xiidra following its $62 billion acquisition …

Advertiser